28th June 2011
Argenta Signs Integrated Services Agreement with Pulmagen Therapeutics
Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects.
Read this article
31st May 2011
AstraZeneca and Heptares Collaborate to Investigate Important GPCR Drug Targets
AstraZeneca and Heptares Therapeutics have announced that they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.
Read this article
9th May 2011
Heptares Grants Shire an Exclusive Option to License Novel Adenosine A2a Antagonist
Heptares Therapeutics has announced that it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2a antagonist discovered by Heptares and currently in preclinical development.
Read this article
20th April 2011
Lombard Medical Announces £27.5 million Financing
Lombard Medical Technologies PLC (AIM: LMT), the specialist medical devices company, has announced a £27.5 million financing, with Abingworth LLP and MVM Life Science Partners LLP who have committed to invest, in aggregate, up to £13.0 million.
Read this article
11th April 2011
Heptares and Takeda Initiate Drug Discovery Collaboration
Heptares and Takeda initiate drug discovery collaboration focused on GPCR linked to CNS disorders. The deal includes £4.5 million upfront cash and equity, up to £60.5 million in future milestone payments, and royalties on product sales.
Read this article
News Archive
Last 5 Articles | Next 5 Articles
24th January 2011BioVex to be acquired by Amgen for up to $1bn
Amgen (Nasdaq: AMGN) and Biovex Group, Inc. today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc., a privately held, venture-funded, biotechnology company headquartered in Woburn, Mass. BioVex is developing OncoVEX(GM-CSF), a novel oncolytic vaccine in Phase 3 clinical development, that may represent a new approach to treating melanoma and head and neck cancer.
Under terms of the agreement, Amgen will pay up to $1 billion: $425 million in cash at closing and up to $575 million in additional payments upon the achievement of certain regulatory and sales milestones. The transaction has been approved by the boards of directors of each company. It is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2011. Following the completion of the transaction, BioVex will become a wholly owned subsidiary of Amgen.
"OncoVex has demonstrated encouraging anti-tumor activity in clinical studies for the treatment of melanoma and head and neck cancer, and BioVex is currently enrolling patients into pivotal Phase 3 trials in both indications," said Roger M. Perlmutter, M.D., Ph.D., Amgen's executive vice president, Research and Development. "Amgen is particularly excited about joining with BioVex and its talented staff to focus on advancing this late-stage investigational therapy, with the hope of bringing it to market within the next few years."
"Amgen is ideally positioned to leverage the potential of OncoVEX in multiple solid tumor indications given their impressive oncology franchise and expertise in biologics manufacturing and development," said Philip Astley-Sparke, chief executive officer of BioVex. "We have a shared vision and commitment to bring novel therapeutics to market and we are looking forward to being able to combine our efforts towards this common goal."
| Associated Links Visit BioVex Visit Amgen |
Downloads Full Press Release |